StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.55 | $1.90 | -25.49% | 1.5M |
| 05-12 | $1.90 | $1.72 | -9.47% | 0.3M |
| 05-13 | $1.77 | $1.60 | -9.60% | 0.3M |
| 05-14 | $1.62 | $1.63 | +0.62% | 0.3M |
| 05-15 | $1.45 | $1.28 | -11.38% | 0.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $145.95K | $622.49K | $358.57K | $213.19K |
Operating Income | $-9.21M | $-50.17M | $-23.62M | $-16.61M |
Net Income | $-9.14M | $-46.90M | $-21.15M | $-7.73M |
EPS (Diluted) | $-4.06 | $-35.25 | $-0.62 | $-0.47 |
Total Assets | $21.50M | $24.74M | $44.74M | $46.47M |
Total Liabilities | $5.46M | $4.11M | $4.91M | $5.33M |
Cash & Equivalents | $8.23M | $11.88M | $11.44M | $11.12M |
Free Cash Flow OCF − CapEx | $-7.99M | $-29.84M | $-23.51M | $-17.53M |
Shares Outstanding | 3.60M | 2.10M | 48.14M | 36.18M |
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.